Analyst Rating Update on TherapeuticsMD (TXMD)

TherapeuticsMD (TXMD) : The consensus on TherapeuticsMD (TXMD) based on 4 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.

TherapeuticsMD (TXMD) : Average target price received by TherapeuticsMD (TXMD) is $15.63 with an expected standard deviation of $2.5. The most aggressive target on the stock is $18, whereas the most downbeat target is $13. 4 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy.


TherapeuticsMD (NYSEMKT:TXMD): The stock opened at $7.73 on Wednesday but the bulls could not build on the opening and the stock topped out at $7.79 for the day. The stock traded down to $7.64 during the day, due to lack of any buying support eventually closed down at $7.70 with a loss of -0.13% for the day. The stock had closed at $7.71 on the previous day. The total traded volume was 906,521 shares.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.